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Detection of prostate cancer using a voltammetric
electronic tongue†
Lluís Pascual,a Inmaculada Campos,a José-Luis Vivancos,*a,b,c,d Guillermo Quintás,e,f
Alba Loras,d M. Carmen Martínez-Bisbal,*a,c Ramón Martínez-Máñez,a,c,d,g
Francisco Boronath and José Luis Ruiz-Cerdàd,h
A simple method based on the multivariate analysis of data from
urine using an electronic voltammetric tongue is used to detect
patients with prostate cancer. A sensitivity of 91% and a speciﬁcity
of 73% were obtained to distinguish the urine from cancer patients
and the urine from non-cancer patients.
Prostate cancer (PCa) is the most frequent noncutaneous
malignancy in the male population. In the United States it had
an incidence of 238 590 cases in 2013.1 Currently, testing the
level of prostate specific antigen (PSA) in blood remains the
most widely used procedure for PCa detection. When using a
4.0 ng ml−1 cutoﬀ, the PSA test sensitivity and specificity are
34.9% and 63.1%, respectively.2 However, a high level of serum
PSA is not necessarily evidence of PCa3 and can also be caused
by benign prostatic hyperplasia (BPH), inflammation of the
prostatic gland, urinary retention or rectal palpation.4 More-
over, the PSA test can produce either false-negative results5 or
over-diagnosis which leads to over-treatment of relatively indo-
lent tumours.6 In addition, it is also worth mentioning that
BPH is the most common benign tumor in men, with preva-
lence estimates ranging from 50% for men in their 50s to 90%
for men in their 90s.7 In this scenario, important studies have
been conducted in the last decade to investigate new pro-
cedures to improve early PCa diagnosis and PCa risk
prediction.8,9
From another point of view, it is well-known that neoplastic
transformation is related to metabolic alterations which pro-
vides a key to diﬀerentiate tumours from normal tissues via
the recognition of metabolic signatures in either tissues or bio-
fluids. The metabolites of living cells are seen as the end pro-
ducts of the biological hierarchy, starting with activated genes
(genome) and extending over the collection of gene transcripts
(transcriptome) and proteins (proteome). Neoplastic trans-
formation is considered to necessitate metabolic alterations
to provide the bioenergetic and synthetic requirements of
malignancy.10 It is on this basis that alterations to the meta-
bolic signatures within biofluids or tissues reflect changes in
phenotype and function and are the key to diﬀerentiate
tumours from the normal tissues.11–13 Moreover, it is believed
that metabolic alterations precede neoplastic proliferation.
In this context, if such precancerous alterations are related to
detectable metabolites, an early intervention may prevent
cancer development or minimize neoplastic proliferation and
invasion of local or distant structures.14
Following this approach, the changes in the levels of single
metabolites and metabolite ratios have long been investigated
as potential biomarker candidates for PCa.15 Nevertheless, in
the particular case of PCa, the current consensus suggests that
there is not a single metabolite that can be directly related to
the existence of PCa but it is the entire metabolic profile which
is more sensitive in identifying and characterizing prostate
cancer.16 According to this, the use of techniques that are
prone to give a holistic picture of the samples is highly appeal-
ing and may find applications in PCa diagnosis. Most meta-
bolomics studies have been reported on prostate in vivo and
ex vivo in tissues and extracts,17–19 but studies on body fluids,
especially urine, are scarce.19–21 The use of urine to detect PCa
is clearly indicated since it contains products released directly
from the prostate or carried within prostatic cells that are
shed into urine.22 Moreover, urine is collected non-invasively
and requires minimal sample preparation prior to the
analysis.23
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From another field, electronic tongues (e-tongues) have
been introduced as a suitable tool applied to characterize the
attributes of complex systems.24 E-tongues are based on un-
specific sensors usually integrated in an array, and their response
is commonly analysed by using suitable pattern recognition
algorithms.24 The idea of this technique is that although the
specificity of each sensor is low, the combination of several
unspecific sensors entails a very large information potential.
Particularly voltammetric e-tongues have been reported to be
versatile, simple, robust and highly sensitive to changes in the
redox attributes of the samples. E-tongues have found a
number of applications in the classification of complex
systems such as food and water samples.25 However the use of
e-tongues for cancer detection in biofluids is much less
common. A potentiometric e-tongue has been applied to study
urine samples from bladder cancer patients (17 tumors, and
10 controls).26 However, preliminary results using PCA for an
unsupervised analysis did not include an estimate of the pre-
dictive performance of the system. Moreover, potentiometric
e-tongues have also been used to determine urea and creatinine
in urine27 and to detect urinary system dysfunctions and
creatinine levels.26 However, as far as we know, voltammetric
e-tongues have not been applied to the study of urine to detect
PCa.
Voltammetric e-tongues are expected to respond to the pres-
ence of electrochemically-active species. In this context it has
been found from basic research studies that during tumour
growth, protein changes in malignant cells lead to peroxi-
dation of the cell membrane components. It has also been
reported that the levels of glutathione (a naturally occurring
reducing agent in cells) increase for some diseases such as
cancer.28 Moreover certain types of cancer cells are known to
produce substantial amounts of reactive oxygen species
(ROS).29 Prostate cells have a distinct metabolic profile reflect-
ing the production of citrate, PSA and polyamines (spermine
and myo-inositol),30 and citrate, which is a redox-active mole-
cule, is a marker of normal prostate cells.30 Moreover, prostate
is known to contain very high intracellular zinc levels.30
However, when prostate cells undergo neoplastic transform-
ation they have been reported to lose the capacity to accumu-
late zinc and citrate.30 These and other similar changes, which
are envisioned to occur during prostate tumour growth, may
provide an “electrochemical” fingerprint for PCa in urine
samples that might be detected by using an e-tongue.
Based on these concepts, we report herein a study on the
potential use of a simple voltammetric e-tongue based on
metallic electrodes for the detection of PCa from urine samples.
Urine samples were obtained from Caucasian patients
recruited in the urological service in Hospital Universitario y
Politécnico La Fe (Valencia, Spain). A total of 114 samples were
studied using an e-tongue, 71 urine samples from patients
with PCa pre-surgery, 26 urine samples from patients with PCa
post-surgery, and 17 urine samples from patients with BPH (22
+ 17 = 43 urine samples without cancer) as shown in Table 1.
The set of patients with PCa contained both patients with
tumour subsidiaries of active treatment (radical prostatectomy
or radiotherapy) and patients with tumours that fulfilled the
criteria of indolent tumours (only 1 or 2 biopsy cores invaded
by prostate cancer, Gleason score <6, PSA-level at diagnosis
≤10 ng mL−1, clinical stage T1c or T2). The patients of this
later subset were left untreated and included in an active
surveillance program. Table 2 shows the age, PSA, cT, Gleason
score, risk group and the final treatment decision for the PCa
patients included in the study.
When collected, the urine samples were frozen and stored
at −80 °C until analysed. When unfrozen the samples were
centrifuged at 2500 rpm for 5 minutes to eliminate solids and
other insoluble materials and then aliquoted. All the samples
were thawed to room temperature (approximately 21 °C) prior
to analysis. The samples were managed (processed, preserved
and supplied) by Biobanco La Fe, authorized and certified
biobank according to the requisites in Real Decreto 1716/2011
(ref. PT13/0010/0026), and Standard ISO 9001:2008.
The e-tongue used in this study was an array of seven
working electrodes (Ir, Rh, Pt, Au, Ag, Co and Cu) with a purity
of 99.99% and a 2-mm diameter (GoodFellow). The set of elec-
trodes was formed by metal wire electrodes housed inside a
stainless steel cylinder that was used as the body of the
electronic tongue system and as the counter electrode. As the
Table 1 Patient and control samples considered in the study
Group Number Perc. % Control type Number Perc. %
PCa 71 62.3 62.3
Control 43 37.7 Post-prostatectomy 26 22.8
HBP 17 14.9
Table 2 Age and clinical data of patients with PCa (n = 71)
Clinical data Range Number Percentage %
Age (years) 50–65 33 46.5
66–80 38 53.5
PSA (ng ml−1) <5 14 19.7
6–10 44 62.0
10–20 13 18.3
cTa cT1c 21 29.6
cT2b 1 1.4
cT2c 47 66.2
cT3b 2 2.8
Gleason scoreb <6 42 59.2
7 18 25.4
8–10 11 15.4
Risk groupc Low 42 59.2
Intermediate 17 23.9
High 12 16.9
Treatment Active surveillance 22 31.0
Hormonal therapy 2 2.8
Radiotherapy 13 18.3
Radical prostatectomy 34 47.9
a cT is a PCa staging related to the extension and location of the
tumour. bGleason score is based on the histological examination of
the biopsy. It ranges from 2 to 10, with 2 representing the most well-
diﬀerentiated tumours and 10 the least-diﬀerentiated tumours. c Risk
group low means cT2abc and Gleason ≤ 6, intermediate means cT2abc
and Gleason = 7, and high risk means cT3ab or Gleason 8–10.
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reference electrode, a saturated calomel electrode was used.
The e-tongue was controlled with a home-made software appli-
cation that runs on a PC and home-made electronic equip-
ment.31 A Large Amplitude Pulse Voltammetry (LAPV)
waveform24 was applied to all the seven working electrodes in
contact with the urine sample and the resulting current vs.
time profile for each electrode was measured. The LAPV com-
posed of 42 pulses of 30 ms ranging from −1000 to 1000 mV
for noble metals, and −500 to 500 mV for non-noble metals
(see the ESI† for details). Fig. 1A shows the LAPV waveform.
The LAPV waveform was applied five times to each urine
sample.
Finally, the mean of the five records was normalized using
the second pulse which is related to the conductivity of the
solution. This procedure minimizes the response of the
e-tongue to variations in salt concentrations in the diﬀerent
urine samples. The presence of strong electrolytes in the urine
as inorganic salts might have masked the information of PCa
related substances. As an example of the response found,
Fig. 1B shows the current/time response obtained for the Ag
electrode in three diﬀerent urine samples from a patient with
PCa, a PCa patient after radical prostatectomy and a patient
diagnosed with BPH.
Data analysis was performed using MATLAB 2014a (The
Mathworks), and PLS_Toolbox (version: 7.9.3). A schematic
work flow of the experimental approach for the data analysis is
described in Fig. 2. The 114 samples were randomly split into
sets for calibration (66%) and sets for cross-validation (33%).
In all cases, the randomly selected calibration sets included a
total of 76 samples containing 47 patients with PCa and
29 control samples (17 after radical prostatectomy and 12 diag-
nosed with BPH). Besides the cross-validation sets included
38 samples containing 24 patients with PCa and 14 control
samples (9 after radical prostatectomy and 5 with BPH).
From the data collected, studies were performed to evaluate
the best selection of electrodes using a two-level full factorial
design for 7 electrodes obtaining 127 experiments or combi-
nation of electrodes.
The initial PLSDA figures of merit for the diﬀerent combi-
nations of electrodes were obtained after 12 iterations of a
random 8-fold. The calibration set was used for model develop-
ment. Supervised discriminant analysis was performed using
partial least squares (PLSDA) and a maximum number of
7 latent variables (LVs). The X-block (i.e. data of combination
of electrodes) was auto-scaled and the y vector containing class
labels (i.e. −1 and +1 for control and PCa samples, respectively)
was mean centred. From the model 4 LVs were retained. In
order to avoid overoptimistic results, the statistical significance
of the model was evaluated using cross-validation. To ensure
the representativeness of the results, the random dataset divi-
sion was repeated 500 times, and the number of misclassifi-
cations was used for the selection of the best combination of
electrodes (vide infra).
Fig. 1 (A) The pulse sequence applied and (B) the current/time
response obtained for a certain electrode (Ag) for three diﬀerent urine
samples from a patient with PCa (PCa), a PCa patient after radical pros-
tatectomy (Prost) and a patient diagnosed with benign prostatic hyper-
plasia (BPH). Fig. 2 Schematic work ﬂow of the experimental approach.
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Fig. 3 depicts the best selection of each combination of
electrodes (using 1 to 7 electrodes) represented by a boxplot
and the number of misclassifications in the cross-validation
sets. The best results were observed when using data from
three (Ir, Au, Ag), four (Ir, Pt, Au, Ag) and five (Ir, Rh, Pt, Au,
Ag) electrodes. For instance, as shown in Fig. 3, when data
from Ir, Au and Ag electrodes (combination C in Fig. 3) were
used to predict PCa in 500 randomly cross-validated subsets,
the median of misclassifications was 7 out of 38, and in
75% of the cases (in 375 out of 500 cross-validated subsets)
misclassifications were equal or lower than 9. The simple
use of one (Pt, combination A in Fig. 3) or two (Ir, Rh, com-
bination B in Fig. 3) electrodes resulted in a worse classifi-
cation indicating that it is the combination of the data of
several electrodes that led to a better sorting of the samples.
When six or seven electrodes were used (see Fig. 3 combi-
nations F and G respectively) the number of misclassifi-
cations also increased. Fig. 3 also shows that the
combination of 4 and 5 electrodes (combinations D and E,
respectively) gave a number of similar misclassified samples
than the combination of 3 electrodes. On the basis of these
results the combination of 3 electrodes (i.e. Ir, Au and Ag, C
in Fig. 3) was selected, being the simplest combination of
metals with the better results (a smaller number of metal
electrodes for the same misclassified samples). This combi-
nation of three electrodes was used for the calculation of a
second PLSDA model (see the ESI† for calculations on
models D and E).
In this second PLSDA model three LVs were used based on
the results obtained after 12 iterations of a random 8-fold (see
the ESI† for details). To avoid overoptimistic results, the stat-
istical significance of the model was evaluated using the exter-
nal validation set which consisted of a total of 37 urine
samples (22 PCa urine samples and 15 control urine samples).
The results are summarized in Table 3, whereas the predicted
values are also shown in Fig. 4.
In this testing phase the use of data from the combination
of Ir, Au and Ag electrodes in urine samples was able to cor-
rectly classify 20 samples out of 22 for the patients with PCa,
whereas it classified 11 samples out of 15 correctly from
control patients. This resulted in a sensitivity of 91% and a
specificity of 73%.
Positive predictive values were 0.833 with lower 0.626 and
upper 0.953 (estimation at 95%). Negative predictive values
were 0.846 with lower 0.546 and upper 0.981 (estimation at
95%). Moreover, a revision of the misclassified data indicated
that the two samples that were predicted as false negatives in
Table 3 belonged to patients with indolent tumours and if
these data are excluded in the validation set, a sensitivity of
100% was reached.
The scientific basis of this ability of e-tongues to detect a
signature of PCa is likely linked to the presence of certain sub-
stances that are released either directly into the urine or
carried within prostatic cells that are shed into urine. Besides,
these preliminary data might reflect the existence of a poten-
tial “electrochemical” signature of PCa in urine samples.
Fig. 3 Boxplot of the best selection for each combination of electrodes
in terms of the number of misclassiﬁcations after 500 iterations in the
cross-validation set (4 LVs). (A) Ag, (B) Ir, Rh, (C) Ir, Au, Ag, (D) Ir, Pt, Au,
Ag, (E) Ir, Rh, Pt, Au, Ag, (F) Ir, Rh, Pt, Au, Ag, Cu, (G) Ir, Rh, Pt, Au, Ag, Co,
Cu.
Table 3 Calibration and validation results obtained by PLSDA using Ir,
Au and Ag electrodes and 3 LVs. 74 for calibration and 37 for validation
Calibration Validation
PCa Control PCa Control
Predicted as PCa 41 0 20 4
Predicted as control 5 28 2 11
46 28 22 15
Fig. 4 Prediction of calibration and validation datasets (3 LVs) using Ir,
Au and Ag electrodes. Split into calibration and validation using the
Kennard–Stone method at 66%. The model has been created using
2 classes (PCa and control) only for visualization purpose. Samples from
patients after radical prostatectomy (Prost) and BPH patients are shown.
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However these electroactive molecules remain unknown for
the moment and should be assessed by specific HPLC-MS and
NMR analysis which are currently being performed.
Conclusions
PCa detection has been pursued using a large variety of tech-
niques and studying diﬀerent kinds of samples such as
tumour tissue extracts and diﬀerent body fluids. Although
these studies have increased the biological understanding of
PCa, they usually fail in providing a picture of the malignancy
status. The current agreement is that entire metabolic profiles
are more sensitive in identifying PCa rather than the changes
of a unique metabolite.
We have shown here that after training, a simple e-tongue
based on metallic electrodes was able to distinguish urine
samples from patients with prostate cancer PCa from non-
cancer urine samples (patients after radical prostatectomy and
patients diagnosed with BPH) with a sensitivity of 91% and a
specificity of 73%. In particular the e-tongue correctly classi-
fied 20 samples out of 22 for patients with PCa, whereas it
classified 11 samples out of 15 correctly from non-cancer
urine samples. Moreover, it is also noteworthy that potential
biases that could have arisen from the presence of other dis-
eases or particular food and drink consumption were not
explored in our protocol but despite this lack of information,
the e-tongue was able to overcome these potential confound-
ing factors. This might rely on the detection of changes in the
“electrochemical profile” informative of a pathological con-
dition, better than reporting the changes of single metabolites
that might be implied in diverse pathologies. The specificity
and sensitivity obtained by the e-tongue in urine is higher
compared to the PSA test in blood which is the most widely
used procedure for PCa detection. The results we have
obtained are of interest and point towards the potential use of
e-tongues in the identification of patients with PCa using low
cost equipment and a simple and fast analysis procedure with
voltammetric e-tongues in urine, which is a body fluid easy to
obtain and in a non-invasive way.
Despite the fact that the roadmap from these results to
an extended use of the e-tongue test in clinical practice
remains long and uncertain, given the relatively low cost
of e-tongues and the potential automatization of sample
measurement and multivariate statistical analysis, the proof
of principle presented here suggests that this simple
approach might have great potential for clinical applications
for both PCa diagnosis and simple monitoring of patients
after therapy.
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64139-C4-1-R (MINECO/FEDER)), the Generalitat Valenciana
(project PROMETEOII/2014/047) and CIBER-BBN (NANO-
PROBE project) for their financial support. A. L. is grateful
to the Generalitat Valenciana for her grant (Vali+d ACIF:
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